Tirzepatide 40mg Pen – GLP-1/GIP Weight Management Injection

Tirzepatide 40mg Pen

The Tirzepatide 40mg Pen shown on this page is presented as a product reference for information about tirzepatide, its mechanism of action, labeled specifications and regulatory information.

What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It acts on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.

Tirzepatide is the active ingredient in FDA-approved medicines including Zepbound and Mounjaro. Zepbound is approved for certain adults with obesity or overweight with a weight-related condition as an adjunct to a reduced-calorie diet and increased physical activity. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Tirzepatide 40mg Pen Specifications

Product Name: Tirzepatide 40mg Pen
Brand: Synedica
Active Ingredient: Tirzepatide
Labeled Total Quantity: 40mg
Pen Label: 10mg
Packaging Shown: 4 × 10mg doses
Receptor Activity: GIP and GLP-1
Dosage Form: Injection pen
Administration Shown: Subcutaneous
Frequency Shown on Packaging: Once weekly
Product Category: Weight Management

How Tirzepatide Works

Tirzepatide activates both GIP and GLP-1 receptors. These receptors are involved in glucose regulation, appetite and metabolic processes. Tirzepatide has been extensively evaluated in clinical research and is the active ingredient in approved medicines with specific indications.

Tirzepatide Clinical Information

Clinical studies have evaluated tirzepatide in areas including type 2 diabetes, weight management and obesity-related conditions. The approved indication depends on the specific tirzepatide medicine, formulation and regulatory jurisdiction.

Important Regulatory Information

The specifications above describe the packaging visible in the product image. They should not be interpreted as confirmation that this specific Synedica product is FDA-approved, manufactured by an FDA-approved manufacturer, or equivalent to Zepbound or Mounjaro.

FDA approval applies to specific drug products, formulations, manufacturers and labeling. Always verify the regulatory status and source of a specific product before making medical or regulatory claims.

Important Safety Information

Approved tirzepatide labeling contains important warnings, contraindications and precautions. Anyone considering tirzepatide treatment should consult an appropriately licensed healthcare professional and review the official prescribing information for the specific approved product.

Product Name: Tirzepatide 40mg Pen
Brand: Synedica
Active Ingredient: Tirzepatide
Total Labeled Quantity: 40mg
Pen Strength Shown: 10mg
Package Configuration: 4 × 10mg doses
Receptor Targets: GIP and GLP-1
Dosage Form: Injection Pen
Administration: Subcutaneous
Frequency Shown: Once Weekly
Product Category: Weight Management
Product Type: Tirzepatide Pen

Related Weight Management Information

Explore our weight management resources for additional information about products and topics related to metabolic health.

For related information, visit our tirzepatide category and explore other relevant weight management products and resources.

Outbound Link 1 — FDA

Anchor text:
FDA Zepbound prescribing information

Link:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf

Suggested sentence:

For official prescribing information, see the FDA Zepbound prescribing information.

Outbound Link 2 — FDA Safety Information

Anchor text:
FDA information on unapproved GLP-1 drugs

Link:
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Suggested sentence:

For additional safety and regulatory information, see the FDA information on unapproved GLP-1 drugs.